Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

O2‐06‐02: Genome‐Wide Meta‐Analysis of Transcriptome Profiling Identifies Novel Dysregulated Genes Implicated in Alzheimer's Disease
Apostolova, Liana G. , Lin, Kuang, Allen, Mariet , Wang, Xue , Ertekin‐Taner, Nilüfer , Petersen, Ronald , Soares, Holly , Wang, Lisu, Qi, Zhenhao, He, Aiqing, Neuhaus, Isaac , Patel, Vishal , Faber, Kelley, Simmons, Andrew , Weiner, Michael W. , Nho, Kwangsik T. , Kim, Sungeun , Risacher, Shannon L. , Keohane, Aoife , Lunnon, Katie , Hodges, Angela , Burgess, Jeremy D. , Singh, Parul , Foroud, Tatiana , Lovestone, Simon , Saykin, Andrew J.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_5 | Pages: No page available

10.1016/j.jalz.2016.06.425 Get It

P2‐079: Assessment of The Known and Candidate Alzheimer's Disease Genes in African‐Americans
N’Songo, Aurelie, Carrasquillo, Minerva M. , Wang, Xue , Nguyen, Thuy , Asmann, Yan W. , Younkin, Steven G. , Graff‐Radford, Neill R. , Ertekin‐Taner, Nilüfer , Carrasquillo, Minerva M. , Burgess, Jeremy D.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_13 | Pages: No page available

10.1016/j.jalz.2016.06.1284 Get It

P3‐285: Patch‐Based Sparse Coding and Multivariate Surface Morphometry for Predicting Amnestic Mild Cognitive Impairment and Alzheimer’S Disease in Cognitively Unimpaired Individuals
Zhang, Jie , Li, Qingyang , Bauer, Robert, Reiman, Eric M. , Caselli, Richard J. , Stonnington, Cynthia M. , Wang, Yalin , Shi, Jie , Chen, Kewei

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_19 | Pages: No page available

10.1016/j.jalz.2016.06.1939 Get It

P4‐027: Combing Evidence Across Multiple Cohorts for Systems‐Based Target Discovery: the AMP‐AD Knowledge Portal
Allen, Mariet , Funk, Corey, Xu, Jishu , Logsdon, Ben , Yu, Lei , Schuyler, Sarah, Friend, Stephen , Schadt, Eric , Jager, Philip L. De , Ertekin‐Taner, Nilüfer , Dang, Kristen K. , Perumal, Thanneer Malai , Wang, Minghui , Bennett, David A. , Zhang, Bin , Price, Nathan D. , Mangravite, Lara M.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_21 | Pages: No page available

10.1016/j.jalz.2016.06.2116 Get It

Multi‐institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non–small cell lung tumors
Shostrom, Valerie , Kumar, Sameera , Zhen, Weining, Hallemeier, Christopher L. , Holland, John , Harkenrider, Matthew M. , Iskhanian, Adrian S., Neboori, Hanmanth J., Attia, Albert, Lee, Percy , Alite, Fiori , Walker, Joshua M. , Stahl, John M. , Wang, Kyle , Bingham, Brian , Hadzitheodorou, C., Decker, Roy H. , McGarry, Ronald C., Simone, Charles B. , Verma, Vivek , Hallemeier, Christopher Leigh , Braunstein, Steve , Jabbour, Salma K , Simone, Charles B

Mayo Clinic

Cancer | October 14, 2016 | Volume: 123 | Issue: 4 | Pages: 688-696

10.1002/cncr.30375 | PMID 27741355 Get It

BACKGROUNDStereotactic body radiotherapy (SBRT) is the standard of care for patients with nonoperative, early‐stage non–small cell lung cancer (NSCLC) measuring < 5 cm, but its use among patients with tumors measuring ≥5 cm is considerably less defined, with the existing literature limited to small, single‐institution reports. The current multi‐institutional study reported outcomes evaluating the largest such population reported to date.METHODSClinical/treatment characteristics, outcomes, toxicities, and patterns of failure were assessed in patients with primary NSCLC measuring ≥5 cm without evidence of distant/lymph node metastasis who underwent SBRT using ≤5 fractions. Statistics included Kaplan‐Meier survival analyses and univariate/multivariate Cox proportional hazards models.RESULTSA total of 92 patients treated from 2004 through 2016 were analyzed from 12 institutions. The median follow‐up was 12 months (15 months in survivors). The median age and tumor size among the patients were 73 years (range, 50‐95 years) and 5.4 cm (range, 5.0‐7.5 cm), respectively. The median dose/fractionation was 50 Gray/5 fractions. The actuarial local control rates at 1 year and 2 years were 95.7% and 73.2%, respectively. The disease‐free survival rate was 72.1% and 53.5%, respectively, at 1 year and 2 years. The 1‐year and 2‐year disease‐specific survival rates were 95.5% and 78.6%, respectively. The median, 1‐year, and 2‐year overall survival rates were 21.4 months, 76.2%, and 46.4%, respectively. On multivariate analysis, lung cancer history and pre‐SBRT positron emission tomography maximum standardized uptake value were found to be associated with overall survival. Posttreatment failures were most commonly distant (33% of all disease recurrences), followed by local (26%) and those occurring elsewhere in the lung (23%). Three patients had isolated local failures. Grade 3 to 4 toxicities included 1 case (1%) and 4 cases (4%) of grade 3 dermatitis and radiation pneumonitis, respectively (toxicities were graded according to the Common Terminology Criteria for Adverse Events [version 4.0]). Grades 2 to 5 radiation pneumonitis occurred in 11% of patients. One patient with a tumor measuring 7.5 cm and a smoking history of 150 pack‐years died of radiation pneumonitis.CONCLUSIONSThe results of the current study, which is the largest study of patients with NSCLC measuring ≥5 cm reported to date, indicate that SBRT is a safe and efficacious option. Cancer 2017;123:688–696. © 2016 American Cancer Society.
Left Atrial Remodeling and Atrioventricular Coupling in a Canine Model of Early Heart Failure With Preserved Ejection Fraction
Zakeri, Rosita , Chai, Qiang , Ogut, Ozgur, Takahama, Hiroyuki , Lü, Tong , Wang, Xiaoli , Linke, Wolfgang A. , Lee, Hon-Chi, Redfield, Margaret M. , Moulay, Gilles , Hussain, Saad, Chai, Qiang, Hussain, Saad Abdulrahman , Wang, Xiao-Li, Lu, Tong , Linke, Wolfgang A , Zakeri, Rosita

Mayo Clinic

Circulation: Heart Failure | October 11, 2016 | Volume: 9 | Issue: 10 | Pages: No page available

10.1161/circheartfailure.115.003238 | PMID 27758811 Get It

Background— Left atrial (LA) compliance and contractility influence left ventricular stroke volume. We hypothesized that diminished LA compliance and contractile function occur early during the development of heart failure with preserved ejection fraction (HFpEF) and impair overall cardiac performance. Methods and Results— Cardiac magnetic resonance imaging, echocardiography, left ventricular and LA pressure-volume studies, and tissue analyses were performed in a model of early HFpEF (elderly dogs, renal wrap-induced hypertension, exogenous aldosterone; n=9) and young control dogs (sham surgery; n=13). Early HFpEF was associated with LA enlargement, cardiomyocyte hypertrophy, and enhanced LA contractile function (median active emptying fraction 16% [95% confidence interval, 13–24]% versus 12 [10–14]%, P =0.008; end-systolic pressure-volume relationship slope 2.4 [1.9–3.2]mm Hg/mL HFpEF versus 1.5 [1.2–2.2]mm Hg/mL controls, P =0.01). However, atrioventricular coupling was impaired and the curvilinear LA end-reservoir pressure-volume relationship was shifted upward/leftward in HFpEF (LA stiffness constant [β LA ] 0.16 [0.11–0.18]mm Hg/mL versus 0.06 [0.04–0.10]mm Hg/mL controls; P =0.002), indicating reduced LA compliance. Impaired atrioventricular coupling and lower LA compliance correlated with lower left ventricular stroke volume. Total fibrosis and titin isoform composition were similar between groups; however, titin was hyperphosphorylated in HFpEF and correlated with β LA . LA microvascular reactivity was diminished in HFpEF versus controls. LA microvascular density tended to be lower in HFpEF and inversely correlated with β LA . Conclusions— In early-stage hypertensive HFpEF, LA cardiomyocyte hypertrophy, titin hyperphosphorylation, and microvascular dysfunction occur in association with increased systolic and diastolic LA chamber stiffness, impaired atrioventricular coupling, and decreased left ventricular stroke volume. These data indicate that maladaptive LA remodeling occurs early during HFpEF development, supporting a concept of global myocardial remodeling.
Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy
Goss, Paul E. , Shepherd, Lois E. , Chapman, J. W. , Chen, Bingshu E. , Kubo, Michiaki , Furukawa, Yoichi , Momozawa, Yukihide , Stearns, Vered , Barman, Poulami , Weinshilboum, Richard M. , Kalari, Krishna R. , Wang, Liewei , Xie, Fang , Ingle, James N. , Xie, Fang , Ellis, Matthew J. , Chapman, Judith‐Anne W. , Pritchard, Kathleen I. , Carlson, Erin E. , Goetz, Matthew P. , Weinshilboum, Richard M. , Stearns, Vered , Chen, Bingshu E , Kalari, Krishna R

Mayo Clinic

Cancer Research | October 11, 2016 | Volume: 76 | Issue: 23 | Pages: 7012-7023

10.1158/0008-5472.can-16-1371 | PMID 27758888 Get It

Abstract Genetic risks in breast cancer remain only partly understood. Here, we report the results of a genome-wide association study of germline DNA from 4,658 women, including 252 women experiencing a breast cancer recurrence, who were entered on the MA.27 adjuvant trial comparing the aromatase inhibitors (AI) anastrozole and exemestane. Single-nucleotide polymorphisms (SNP) of top significance were identified in the gene encoding MIR2052HG, a long noncoding RNA of unknown function. Heterozygous or homozygous individuals for variant alleles exhibited a ∼40% or ∼63% decrease, respectively, in the hazard of breast cancer recurrence relative to homozygous wild-type individuals. Functional genomic studies in lymphoblastoid cell lines and ERα-positive breast cancer cell lines showed that expression from MIR2052HG and the ESR1 gene encoding estrogen receptor-α (ERα) was induced by estrogen and AI in a SNP-dependent manner. Variant SNP genotypes exhibited increased ERα binding to estrogen response elements, relative to wild-type genotypes, a pattern that was reversed by AI treatment. Further, variant SNPs were associated with lower expression of MIR2052HG and ERα. RNAi-mediated silencing of MIR2052HG in breast cancer cell lines decreased ERα expression, cell proliferation, and anchorage-independent colony formation. Mechanistic investigations revealed that MIR2052HG sustained ERα levels both by promoting AKT/FOXO3-mediated ESR1 transcription and by limiting ubiquitin-mediated, proteasome-dependent degradation of ERα. Taken together, our results define MIR2052HS as a functionally polymorphic gene that affects risks of breast cancer recurrence in women treated with AI. More broadly, our results offer a pharmacogenomic basis to understand differences in the response of breast cancer patients to AI therapy. Cancer Res; 76(23); 7012–23. ©2016 AACR.
A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
Rosen, Lee S. , Algazi, Alain P. , Moser, Brian A., Hu, Tianle, Wang, Xuejing Aimee , Tuttle, Jay , Wooldridge, James E. , Banck, Michaela S., Banck, Michaela, Goldman, Jonathan W. , Turner, P. Kellie , Wacheck, Volker

Mayo Clinic

Clinical Cancer Research | October 11, 2016 | Volume: 23 | Issue: 8 | Pages: 1910-1919

10.1158/1078-0432.ccr-16-1418 | PMID 27803065 Get It

Abstract Purpose: The MET/HGF pathway regulates cell proliferation and survival and is dysregulated in multiple tumors. Emibetuzumab (LY2875358) is a bivalent antibody that inhibits HGF-dependent and HGF-independent MET signaling. Here, we report dose escalation results from the first-in-human phase I trial of emibetuzumab. Experimental Design: The study comprised a 3+3 dose escalation for emibetuzumab monotherapy (Part A) and in combination with erlotinib (Part A2). Emibetuzumab was administered i.v. every 2 weeks (Q2W) using a flat dosing scheme. The primary objective was to determine a recommended phase II dose (RPTD) range; secondary endpoints included tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity. Results: Twenty-three patients with solid tumors received emibetuzumab monotherapy at 20, 70, 210, 700, 1,400, and 2,000 mg and 14 non–small cell lung cancer (NSCLC) patients at 700, 1,400, and 2,000 mg in combination with erlotinib 150 mg daily. No dose-limiting toxicities and related serious or ≥ grade 3 adverse events were observed. The most common emibetuzumab-related adverse events included mild diarrhea, nausea, and vomiting, and mild to moderate fatigue, anorexia, and hypocalcemia in combination with erlotinib. Emibetuzumab showed linear PK at doses &gt;210 mg. Three durable partial responses were observed, one for emibetuzumab (700 mg) and two for emibetuzumab + erlotinib (700 mg and 2,000 mg). Both of the responders to emibetuzumab + erlotinib had progressed to prior erlotinib and were positive for MET protein tumor expression. Conclusions: Based on tolerability, PK/PD analysis, and preliminary clinical activity, the RPTD range for emibetuzumab single agent and in combination with erlotinib is 700 to 2,000 mg i.v. Q2W. Clin Cancer Res; 23(8); 1910–9. ©2016 AACR.
The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers
Wang, Zhaoming , Schumacher, Fredrick R. , Gayther, Simon A. , Casey, Graham , Sellers, Thomas A. , Gruber, Stephen B., Dunning, Alison M. , Michailidou, Kyriaki , Fachal, Laura , Doheny, Kimberly F. , Li, Yafang , Xiao, Xiangjun , Romm, Jane, Pugh, Elizabeth, Coetzee, Gerhard A. , Hazelett, Dennis J. , Bojesen, Stig E. , Caga-Anan, Charlisse , Haiman, Christopher A. , Kamal, Ahsan , Luccarini, Craig , Tessier, Daniel C., Vincent, Daniel , Bacot, François, Berg, David Van Den , Nelson, Stefanie A. , Demetriades, Stephen, Goldgar, David E., Forman, Judith L., Conti, David V. , Bickeböller, Heike , Risch, Angela , Waldenberger, Mélanie , Brüske‐Hohlfeld, Irene, Hicks, Belynda , McGuffog, Lesley, Kuchenbaecker, Karoline , Soucy, Penny, Manz, Judith, Cunningham, Julie M. , Butterbach, Katja, Kote‐Jarai, Zsofia , Kraft, Peter , Lindström, Sara , Adams, Marcia, McKay, James , Phelan, Catherine M., Benlloch, Sara, Kelemen, Linda E., Brennan, Paul , Riggan, Marjorie J. , O’Mara, Tracy A. , Shen, Hongbing , Shi, Yongyong , Thompson, Deborah J. , Goodman, Marc T. , Nielsen, Sune F. , LaBoissière, Sylvie, Schmit, Stephanie L. , Shelford, Tameka, Edlund, Christopher K., Taylor, Jack A. , Field, John K. , Park, Sue K. , Offit, Kenneth , Thomassen, Mads , Schmutzler, Rita K., Ottini, Laura , Hung, Rayjean J., Olama, Ali Amin Al , Peters, Ulrike , Eeles, Rosalind A. , Seldin, Michael F., Gillanders, Elizabeth M. , Seminara, Daniela, Antoniou, Antonis C. , Chenevix‐Trench, Georgia , Simard, Jacques , Easton, Douglas F. , Durocher, Francine , Hung, Rayjean J. , Amos, Christopher I. , Dennis, Joe , Byun, Jinyoung , Hunter, David J. , Spurdle, Amanda B. , Couch, Fergus J. , Giles, Graham G. , Ling, Hua , Lee, Andrew , FitzGerald, Liesel M. , Berchuck, Andrew , Marchini, Jonathan , Pharoah, Paul D.P. , Chanock, Stephen Jacob , Hazelett, Dennis J , Eeles, Rosalind A , Van Den Berg, David J , Hung, Rayjean J , Wang, Zhaoming , O'Mara, Tracy A , Field, John K , Dunning, Alison M , Michailidou, Kyriaki , Taylor, Jack A , Kraft, Peter , Simard, Jacques , Chenevix-Trench, Georgia , Ottini, Laura , Conti, David V , Bojesen, Stig E , Risch, Angela , Bickeböller, Heike , Shen, Hongbing , Goodman, Marc T , Fachal, Laura

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | October 3, 2016 | Volume: 26 | Issue: 1 | Pages: 126-135

10.1158/1055-9965.epi-16-0106 | PMID 27697780 Get It

Abstract Background: Common cancers develop through a multistep process often including inherited susceptibility. Collaboration among multiple institutions, and funding from multiple sources, has allowed the development of an inexpensive genotyping microarray, the OncoArray. The array includes a genome-wide backbone, comprising 230,000 SNPs tagging most common genetic variants, together with dense mapping of known susceptibility regions, rare variants from sequencing experiments, pharmacogenetic markers, and cancer-related traits. Methods: The OncoArray can be genotyped using a novel technology developed by Illumina to facilitate efficient genotyping. The consortium developed standard approaches for selecting SNPs for study, for quality control of markers, and for ancestry analysis. The array was genotyped at selected sites and with prespecified replicate samples to permit evaluation of genotyping accuracy among centers and by ethnic background. Results: The OncoArray consortium genotyped 447,705 samples. A total of 494,763 SNPs passed quality control steps with a sample success rate of 97% of the samples. Participating sites performed ancestry analysis using a common set of markers and a scoring algorithm based on principal components analysis. Conclusions: Results from these analyses will enable researchers to identify new susceptibility loci, perform fine-mapping of new or known loci associated with either single or multiple cancers, assess the degree of overlap in cancer causation and pleiotropic effects of loci that have been identified for disease-specific risk, and jointly model genetic, environmental, and lifestyle-related exposures. Impact: Ongoing analyses will shed light on etiology and risk assessment for many types of cancer. Cancer Epidemiol Biomarkers Prev; 26(1); 126–35. ©2016 AACR.